View Financial HealthCore One Labs 배당 및 자사주 매입배당 기준 점검 0/6Core One Labs 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 10Core One Labs Inc. announced that it expects to receive CAD 1.5 million in fundingCore One Labs Inc. announced a non-brokered private placement of 10,000,000 units at a price of CAD 0.15 per unit for gross proceeds of up to CAD 1,500,000 on April 9, 2024. Each unit consists of one common share and one half of one transferable share purchase warrant. Each whole warrant entitles the holder thereof to purchase one additional share of the company for a period of five years from issuance, at a price of CAD 0.20 per share. Closing of the first tranche of the Private Placement is anticipated to occur on or about April 17, 2024. Pursuant to applicable securities laws, all securities issued under the Private Placement will be subject to restrictions on resale for a period of four months and one day. The company does not anticipate paying any finder’s fees related to the Private Placement.공시 • Dec 07Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio- Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment MethodsCore One Labs Inc. share the exciting results of its first round of Stage 2 animal model studies, carried out in collaboration with the Universitat de Barcelona on behalf of the Company's wholly owned subsidiary, Akome Biotechnologies Inc. The results of the studies so far demonstrate promising outcomes, showing potential to outperform current treatment methods for Alzheimer's and Parkinson's, and marking a significant step forward in the Company's pursuit of innovative treatment alternatives for common neurodegenerative diseases and mental health conditions. These Stage 2 animal model studies mark the initial phase in the exploration of Akome's five plant bioactives (the "Bio-Compounds"), both individually and in conjunction with the psychedelic compound N, N-dimethyltryptamine ("DMT" or the "Psychedelic Compound"), in their ability to mitigate, or eliminate disrupted physiological processes associated with a variety of neurological and mental health disorders, including Alzheimer Disease ("Alzheimer's"), Parkinson's Disease ("Parkinson's"), Ischemic Stroke and Depression. These studies focus on the motility of a specific C. elegans strain known as "CL2006" (the " animal model" or the " model"). During the initial round of Stage 2 animal model study, five distinct dose-response assay sets were executed to investigate the effects on motility of the CL2006 strain of five bio-compounds when combined with DMT. The results showed a significant improvement in the motility of CL2006 C. elegans strain after exposure to combination of Bio-Compounds and DMT, surpassing the effects observed when they are administered individually. Moreover, the assays revealed a complete absence of toxicity in the model when the Bio-Compounds and the Psychedelic Compound were administered together. These results represent a significant milestone and mark a vital step toward identifying the optimal combination of Bio- Compounds and DMT for advanced animal studies using models like mice or rats. The compelling outcomes from these dose-response assays have ignited a profound sense of optimism within Core One's research team, prompting the decision to initiate further Stage 2 studies. These new studies will explore elevated concentration levels of Bio-Compounds while maintaining a consistent concentration of the Psychedelic Compound in order to decrease the potential of treatment-limiting side effects. Building on the preliminary results of today's first round of Stage 2 studies, Core One's researchers hypothesize that the reduction of motor dysfunction in the model will be further enhanced with increased concentrations of the patent-pending bio-compounds. The Company's investigators are also poised to conduct these dose-response assay studies with combination of Akome Bio-Compounds and additional psychedelic compounds in the coming months, continuing their scientific journey in hopes of bringing science closer to groundbreaking therapeutic breakthroughs, inspiring hope and opening doors to new horizons in the field of neuroscience.공시 • Sep 20Core One Labs Inc. announced that it has received CAD 0.2 million in fundingOn September 18, 2023, Core One Labs Inc. closed the transaction. The company issued 625,000 units at a price of CAD 0.32 per unit for gross proceeds of CAD 200,000. Each unit consists of one share and one transferable share purchase warrant. Each warrant entitles the holder thereof to purchase one additional share of the company for a period of five years at a price of CAD 0.43 per share. In connection with closing, the Company issued 12,500 Shares ("Administrative Shares") to Amalfi Corporate Services Ltd., in consideration for administrative services rendered in connection with the Private Placement. Pursuant to applicable securities laws, all securities issued under the Private Placement are subject to a statutory hold period of four months and a day expiring on January 19, 2024.공시 • Sep 12Core One Labs Inc. announced that it expects to receive CAD 1 million in fundingCore One Labs Inc. announced a non-brokered private placement to issue 3,125,000 units at an issue price of CAD 0.32 per Unit, for gross proceeds of CAD 1,000,000 on September 11, 2023. Each Unit will consist of one common share and one common share purchase warrant. Each Warrant will entitle the holder, on exercise, to purchase one Share for a period of five years at an exercise price of CAD 0.43 per Share. In connection with the Financing, the Company may pay finders’ fees and/or issue finders’ warrants on the same terms as the Warrants, to eligible parties who have assisted by introducing subscribers to the Financing. Pursuant to applicable securities laws, all securities issued under the Financing will be subject to a statutory hold period of four months and one day. Closing of the proposed Financing is anticipated to occur on or about September 18, 2023.공시 • Aug 05Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's DiseaseCore One Labs Inc. announced the receipt of additional positive results from its second round of Stage 1 animal model studies. The studies were conducted in collaboration with esteemed research partners at the Universitat de Barcelona, Spain, and were carried out on behalf of Core One's wholly owned subsidiary, Akome Biotechnologies Inc. (Akome). These additional positive results come from the animal model studies that tested five carefully selected bioactive compounds based on their ability to mitigate, or eliminate disrupted physiological processes associated with a variety of neurological and mental health disorders, including Alzheimer's Disease ("Alzheimer's"), Parkinson's Disease ("Parkinson's"), Ischemic Stroke ("Stroke") and Depression. The fact that Akome is testing five compounds (Bio-Compounds A-E) speaks to the Company's diversified drug pipeline, which will allow Core One to potentially develop a number of different pharmaceuticals targeting a wide range of diseases, thereby increasing the company's revenue potential in the long term. On July 24, 2023, Akome unveiled the initial findings from the first round of Stage 1 animal model studies. These results showcased the potential of the plant bio-active compound referred to as "Bio-Compound A," the first among five bio-compounds being investigated in the Company's five United States Patent and Treaty Office applications. The data from this animal model demonstrated that Bio-Compound A exhibits promising properties in significantly reducing motor dysfunction. This animal model motor dysfunction could be considered a proxy of the motor dysfunction observed in Parkinson's disease and prevalent in the late stages of Alzheimer's disease. Building on this promising foundation, Core One's investigators have now received positive results for the remaining four bio-compounds, namely Bio-Compounds B through E, in the recently concluded Round 2 Stage 1 animal model studies. These studies were meticulously designed, following the exact testing criteria employed during Round 1. The animal models were individually exposed to various concentrations of the respective Bio-Compounds, and their motility was closely evaluated compared to a control sample of animal models not exposed to the Bio-Compounds. The data from Round 2 studies for each of Bio-Compounds B, C, D, and E demonstrated significant improvement in the animal models' motility when compared to the control sample. Additionally, investigators observed that as the dose concentration of the respective Bio-Compounds increased, the improvement in the model's motility also increased, further underlining the significant potential therapeutic value of the patent pending Bio-Compounds. The combined significance of the previously reported Round 1 and the current Round 2 Stage 1 animal model studies underscores the enormous promise of all five bio-compounds currently under investigation. As Core One continues its dedication to drug development and pre-clinical testing, these compounds stand as strong contenders for further evaluation and potential breakthroughs in treating motor dysfunction related to neurological disorders like Parkinson's and Alzheimer's.공시 • Jul 29Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s DiseaseCore One Labs Inc. announced positive results from its first round of Stage 1 animal model studies, conducted by its research partners at the Universitat de Barcelona ("University of Barcelona" or the "University" or the "Investigators"), Barcelona, Spain, on behalf of the company's wholly owned subsidiary, Akome Biotechnologies Inc. (Akome). Akome's Stage 1 animal model studies (in vivo, or within living organisms) use the nematode Caenorhabditis elegans ("C. elegans" or the "model") animal model, and evaluate Akome's carefully selected and various bio-compounds individually in their ability to mitigate, or eliminate disrupted physiological processes associated with a variety of neurological and mental health disorders, including Alzheimer Disease ("Alzheimer's"), Parkinson's Disease ("Parkinson's"), Ischemic Stroke ("Stroke") and Depression, (collectively the "Targeted Diseases"). The first round of these Stage 1 animal model studies focused on examining the pharmacological effects of justone (1) of Akome's five (5) selected plant bioactive compounds ("Bio-Compound A"), after exposure to the central nervous system of the model. Investigators assessed the impact of Bio-Compound A on the motility of a specific C. elegans strain ("CL2006") - a nematode strain containing a transgene responsible for progressive, adult-onset paralysis (which is widely used for Alzheimer's and Parkinson's drug discovery research) and are pleased to share the positive preliminary results. The preliminary results from Bio-Compound A Stage 1 studies have shown favourable effects supporting Akome's hypothesis that Bio-Compound A has the potential to significantly reduce motor dysfunction, a dysfunction associated with Parkinson's, and prevalent in late stages of Alzheimer's. This effect by Bio-Compound A on the CL2006 C. elegans strain model is showing effects similar to those observed in the same model with drugs currently approved for the treatment of Parkinson's disease. The significance of Bio-Compound A having similar results to that of currently approved Parkinson's drug treatments, is that Bio-Compound A is a natural plant derivative. These extremely promising and positive initial results from the Stage 1 animal model study for Bio-Compound A holds substantial significance for Akome's further progression toward advanced animal model studies. In the upcoming weeks, the Company anticipates presenting results from additional Stage 1 animal model studies for the remaining Akome bio-compounds, and targeted diseases which are the subject of the Company's patent-pending psychedelic drug formulations. Following results from the remaining Akome bio-compound Stage 1 studies, Investigators will proceed with Stage 2 animal model studies, examining the synergistic effect of the bio-compounds in combination with N, N-dimethyltryptamine ("DMT") and other psychedelic compounds.공시 • Jan 25Core One Labs Inc. Announces Management ChangesCore One Labs Inc. announced the appointment of Dr. Santiago Ferro, Chief Executive Officer of Akome, to the Company's board of directors. Dr. Ferro is a world-renowned physician with over 20 years' experience in pharmaceuticals, biologicals and biotech industries. Dr. Ferro has held many prestigious senior research and development positions with global responsibilities for clinical development programs, design, implementation, and analysis of clinical trials data, and has a proven record of generating and building relationships, managing projects from concept to completion, as well as designing clinical plans to meet market targets and bringing products to success. A graduate of Javeriana University Medical School in his native Bogotá, Colombia, Dr. Ferro specialized in Internal Medicine, and later received his sub-specialty training in Infectious Diseases at the University of Toronto. Following completion of his medical and specialty training, he returned to Bogotá and established a private practice in both Internal Medicine and Infectious Diseases, while at the same time holding academic positions at different teaching hospitals. Over the years, Dr. Ferro built a distinguished reputation in his fields of study, having over twenty-five scientific publications in peer reviewed journals and medical textbooks; and being featured in multiple international scientific conferences. Dr. Ferro will continue in his role as Chief Execute Officer of Akome as well as Chief Medical Officer of Core One. The Company also announced that, effective immediately, Dr. Robert E.W. Hancock, OC, PhD, OBC, will step down as Chairman and Director from the Company's board of directors, and dedicate his time in a new appointment as Head of Scientific Development for Vocan Biotechnologies Inc. ("Vocan"), a wholly-owned subsidiary of Core One. In this capacity, Dr. Hancock will continue to build and nurture Vocan's growth through his invaluable expertise and insight into the psychedelics industry.공시 • Jan 15Core One Labs Inc. (CNSX:COOL) acquired GMP Drug Inc. for CAD 3.5 million.Core One Labs Inc. (CNSX:COOL) acquired GMP Drug Inc. for CAD 3.5 million on January 13, 2023. The acquisition was completed pursuant to a share purchase agreement among the company, GMP Drug and the shareholders of GMP Drug (the “Definitive Agreement”) dated January 13, 2022. Pursuant to the definitive agreement, and in consideration for the acquisition of GMP Drug, Core One issued 4,117,647 common shares (the “Consideration Shares”) at a deemed price of CAD 0.68 per consideration share for a total purchase price of CAD 2,800,000. In addition to the consideration shares, the existing shareholders of GMP Drug are entitled to receive a bonus of 1,029,412 common shares of Core One (the “Bonus Shares”). The bonus shares will be issuable upon successful completion of a trial production run of a psychedelic compound at the facility. In connection with the completion of the acquisition, the company has issued 82,353 shares to Amalfi Corporate Services Ltd. (the “Administrative Fee Shares”) who assisted with facilitating the acquisition and provided administrative support for its completion. The consideration shares, administrative shares and bonus shares are not subject to restrictions on resale. GMP Drug holds the rights to operate from the facility for a twelve-month term ending November 30, 2023. Core One Labs Inc. (CNSX:COOL) completed the acquisition of GMP Drug Inc. on January 13, 2023.공시 • Dec 10Core One Labs Inc., Annual General Meeting, Feb 08, 2023Core One Labs Inc., Annual General Meeting, Feb 08, 2023.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CLAB.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CLAB.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Core One Labs 배당 수익률 vs 시장CLAB.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CLAB.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (CLAB.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CLAB.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CLAB.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CLAB.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CLAB.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 00:47종가2026/05/15 00:00수익2023/03/31연간 수익2023/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Core One Labs Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 10Core One Labs Inc. announced that it expects to receive CAD 1.5 million in fundingCore One Labs Inc. announced a non-brokered private placement of 10,000,000 units at a price of CAD 0.15 per unit for gross proceeds of up to CAD 1,500,000 on April 9, 2024. Each unit consists of one common share and one half of one transferable share purchase warrant. Each whole warrant entitles the holder thereof to purchase one additional share of the company for a period of five years from issuance, at a price of CAD 0.20 per share. Closing of the first tranche of the Private Placement is anticipated to occur on or about April 17, 2024. Pursuant to applicable securities laws, all securities issued under the Private Placement will be subject to restrictions on resale for a period of four months and one day. The company does not anticipate paying any finder’s fees related to the Private Placement.
공시 • Dec 07Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio- Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment MethodsCore One Labs Inc. share the exciting results of its first round of Stage 2 animal model studies, carried out in collaboration with the Universitat de Barcelona on behalf of the Company's wholly owned subsidiary, Akome Biotechnologies Inc. The results of the studies so far demonstrate promising outcomes, showing potential to outperform current treatment methods for Alzheimer's and Parkinson's, and marking a significant step forward in the Company's pursuit of innovative treatment alternatives for common neurodegenerative diseases and mental health conditions. These Stage 2 animal model studies mark the initial phase in the exploration of Akome's five plant bioactives (the "Bio-Compounds"), both individually and in conjunction with the psychedelic compound N, N-dimethyltryptamine ("DMT" or the "Psychedelic Compound"), in their ability to mitigate, or eliminate disrupted physiological processes associated with a variety of neurological and mental health disorders, including Alzheimer Disease ("Alzheimer's"), Parkinson's Disease ("Parkinson's"), Ischemic Stroke and Depression. These studies focus on the motility of a specific C. elegans strain known as "CL2006" (the " animal model" or the " model"). During the initial round of Stage 2 animal model study, five distinct dose-response assay sets were executed to investigate the effects on motility of the CL2006 strain of five bio-compounds when combined with DMT. The results showed a significant improvement in the motility of CL2006 C. elegans strain after exposure to combination of Bio-Compounds and DMT, surpassing the effects observed when they are administered individually. Moreover, the assays revealed a complete absence of toxicity in the model when the Bio-Compounds and the Psychedelic Compound were administered together. These results represent a significant milestone and mark a vital step toward identifying the optimal combination of Bio- Compounds and DMT for advanced animal studies using models like mice or rats. The compelling outcomes from these dose-response assays have ignited a profound sense of optimism within Core One's research team, prompting the decision to initiate further Stage 2 studies. These new studies will explore elevated concentration levels of Bio-Compounds while maintaining a consistent concentration of the Psychedelic Compound in order to decrease the potential of treatment-limiting side effects. Building on the preliminary results of today's first round of Stage 2 studies, Core One's researchers hypothesize that the reduction of motor dysfunction in the model will be further enhanced with increased concentrations of the patent-pending bio-compounds. The Company's investigators are also poised to conduct these dose-response assay studies with combination of Akome Bio-Compounds and additional psychedelic compounds in the coming months, continuing their scientific journey in hopes of bringing science closer to groundbreaking therapeutic breakthroughs, inspiring hope and opening doors to new horizons in the field of neuroscience.
공시 • Sep 20Core One Labs Inc. announced that it has received CAD 0.2 million in fundingOn September 18, 2023, Core One Labs Inc. closed the transaction. The company issued 625,000 units at a price of CAD 0.32 per unit for gross proceeds of CAD 200,000. Each unit consists of one share and one transferable share purchase warrant. Each warrant entitles the holder thereof to purchase one additional share of the company for a period of five years at a price of CAD 0.43 per share. In connection with closing, the Company issued 12,500 Shares ("Administrative Shares") to Amalfi Corporate Services Ltd., in consideration for administrative services rendered in connection with the Private Placement. Pursuant to applicable securities laws, all securities issued under the Private Placement are subject to a statutory hold period of four months and a day expiring on January 19, 2024.
공시 • Sep 12Core One Labs Inc. announced that it expects to receive CAD 1 million in fundingCore One Labs Inc. announced a non-brokered private placement to issue 3,125,000 units at an issue price of CAD 0.32 per Unit, for gross proceeds of CAD 1,000,000 on September 11, 2023. Each Unit will consist of one common share and one common share purchase warrant. Each Warrant will entitle the holder, on exercise, to purchase one Share for a period of five years at an exercise price of CAD 0.43 per Share. In connection with the Financing, the Company may pay finders’ fees and/or issue finders’ warrants on the same terms as the Warrants, to eligible parties who have assisted by introducing subscribers to the Financing. Pursuant to applicable securities laws, all securities issued under the Financing will be subject to a statutory hold period of four months and one day. Closing of the proposed Financing is anticipated to occur on or about September 18, 2023.
공시 • Aug 05Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's DiseaseCore One Labs Inc. announced the receipt of additional positive results from its second round of Stage 1 animal model studies. The studies were conducted in collaboration with esteemed research partners at the Universitat de Barcelona, Spain, and were carried out on behalf of Core One's wholly owned subsidiary, Akome Biotechnologies Inc. (Akome). These additional positive results come from the animal model studies that tested five carefully selected bioactive compounds based on their ability to mitigate, or eliminate disrupted physiological processes associated with a variety of neurological and mental health disorders, including Alzheimer's Disease ("Alzheimer's"), Parkinson's Disease ("Parkinson's"), Ischemic Stroke ("Stroke") and Depression. The fact that Akome is testing five compounds (Bio-Compounds A-E) speaks to the Company's diversified drug pipeline, which will allow Core One to potentially develop a number of different pharmaceuticals targeting a wide range of diseases, thereby increasing the company's revenue potential in the long term. On July 24, 2023, Akome unveiled the initial findings from the first round of Stage 1 animal model studies. These results showcased the potential of the plant bio-active compound referred to as "Bio-Compound A," the first among five bio-compounds being investigated in the Company's five United States Patent and Treaty Office applications. The data from this animal model demonstrated that Bio-Compound A exhibits promising properties in significantly reducing motor dysfunction. This animal model motor dysfunction could be considered a proxy of the motor dysfunction observed in Parkinson's disease and prevalent in the late stages of Alzheimer's disease. Building on this promising foundation, Core One's investigators have now received positive results for the remaining four bio-compounds, namely Bio-Compounds B through E, in the recently concluded Round 2 Stage 1 animal model studies. These studies were meticulously designed, following the exact testing criteria employed during Round 1. The animal models were individually exposed to various concentrations of the respective Bio-Compounds, and their motility was closely evaluated compared to a control sample of animal models not exposed to the Bio-Compounds. The data from Round 2 studies for each of Bio-Compounds B, C, D, and E demonstrated significant improvement in the animal models' motility when compared to the control sample. Additionally, investigators observed that as the dose concentration of the respective Bio-Compounds increased, the improvement in the model's motility also increased, further underlining the significant potential therapeutic value of the patent pending Bio-Compounds. The combined significance of the previously reported Round 1 and the current Round 2 Stage 1 animal model studies underscores the enormous promise of all five bio-compounds currently under investigation. As Core One continues its dedication to drug development and pre-clinical testing, these compounds stand as strong contenders for further evaluation and potential breakthroughs in treating motor dysfunction related to neurological disorders like Parkinson's and Alzheimer's.
공시 • Jul 29Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s DiseaseCore One Labs Inc. announced positive results from its first round of Stage 1 animal model studies, conducted by its research partners at the Universitat de Barcelona ("University of Barcelona" or the "University" or the "Investigators"), Barcelona, Spain, on behalf of the company's wholly owned subsidiary, Akome Biotechnologies Inc. (Akome). Akome's Stage 1 animal model studies (in vivo, or within living organisms) use the nematode Caenorhabditis elegans ("C. elegans" or the "model") animal model, and evaluate Akome's carefully selected and various bio-compounds individually in their ability to mitigate, or eliminate disrupted physiological processes associated with a variety of neurological and mental health disorders, including Alzheimer Disease ("Alzheimer's"), Parkinson's Disease ("Parkinson's"), Ischemic Stroke ("Stroke") and Depression, (collectively the "Targeted Diseases"). The first round of these Stage 1 animal model studies focused on examining the pharmacological effects of justone (1) of Akome's five (5) selected plant bioactive compounds ("Bio-Compound A"), after exposure to the central nervous system of the model. Investigators assessed the impact of Bio-Compound A on the motility of a specific C. elegans strain ("CL2006") - a nematode strain containing a transgene responsible for progressive, adult-onset paralysis (which is widely used for Alzheimer's and Parkinson's drug discovery research) and are pleased to share the positive preliminary results. The preliminary results from Bio-Compound A Stage 1 studies have shown favourable effects supporting Akome's hypothesis that Bio-Compound A has the potential to significantly reduce motor dysfunction, a dysfunction associated with Parkinson's, and prevalent in late stages of Alzheimer's. This effect by Bio-Compound A on the CL2006 C. elegans strain model is showing effects similar to those observed in the same model with drugs currently approved for the treatment of Parkinson's disease. The significance of Bio-Compound A having similar results to that of currently approved Parkinson's drug treatments, is that Bio-Compound A is a natural plant derivative. These extremely promising and positive initial results from the Stage 1 animal model study for Bio-Compound A holds substantial significance for Akome's further progression toward advanced animal model studies. In the upcoming weeks, the Company anticipates presenting results from additional Stage 1 animal model studies for the remaining Akome bio-compounds, and targeted diseases which are the subject of the Company's patent-pending psychedelic drug formulations. Following results from the remaining Akome bio-compound Stage 1 studies, Investigators will proceed with Stage 2 animal model studies, examining the synergistic effect of the bio-compounds in combination with N, N-dimethyltryptamine ("DMT") and other psychedelic compounds.
공시 • Jan 25Core One Labs Inc. Announces Management ChangesCore One Labs Inc. announced the appointment of Dr. Santiago Ferro, Chief Executive Officer of Akome, to the Company's board of directors. Dr. Ferro is a world-renowned physician with over 20 years' experience in pharmaceuticals, biologicals and biotech industries. Dr. Ferro has held many prestigious senior research and development positions with global responsibilities for clinical development programs, design, implementation, and analysis of clinical trials data, and has a proven record of generating and building relationships, managing projects from concept to completion, as well as designing clinical plans to meet market targets and bringing products to success. A graduate of Javeriana University Medical School in his native Bogotá, Colombia, Dr. Ferro specialized in Internal Medicine, and later received his sub-specialty training in Infectious Diseases at the University of Toronto. Following completion of his medical and specialty training, he returned to Bogotá and established a private practice in both Internal Medicine and Infectious Diseases, while at the same time holding academic positions at different teaching hospitals. Over the years, Dr. Ferro built a distinguished reputation in his fields of study, having over twenty-five scientific publications in peer reviewed journals and medical textbooks; and being featured in multiple international scientific conferences. Dr. Ferro will continue in his role as Chief Execute Officer of Akome as well as Chief Medical Officer of Core One. The Company also announced that, effective immediately, Dr. Robert E.W. Hancock, OC, PhD, OBC, will step down as Chairman and Director from the Company's board of directors, and dedicate his time in a new appointment as Head of Scientific Development for Vocan Biotechnologies Inc. ("Vocan"), a wholly-owned subsidiary of Core One. In this capacity, Dr. Hancock will continue to build and nurture Vocan's growth through his invaluable expertise and insight into the psychedelics industry.
공시 • Jan 15Core One Labs Inc. (CNSX:COOL) acquired GMP Drug Inc. for CAD 3.5 million.Core One Labs Inc. (CNSX:COOL) acquired GMP Drug Inc. for CAD 3.5 million on January 13, 2023. The acquisition was completed pursuant to a share purchase agreement among the company, GMP Drug and the shareholders of GMP Drug (the “Definitive Agreement”) dated January 13, 2022. Pursuant to the definitive agreement, and in consideration for the acquisition of GMP Drug, Core One issued 4,117,647 common shares (the “Consideration Shares”) at a deemed price of CAD 0.68 per consideration share for a total purchase price of CAD 2,800,000. In addition to the consideration shares, the existing shareholders of GMP Drug are entitled to receive a bonus of 1,029,412 common shares of Core One (the “Bonus Shares”). The bonus shares will be issuable upon successful completion of a trial production run of a psychedelic compound at the facility. In connection with the completion of the acquisition, the company has issued 82,353 shares to Amalfi Corporate Services Ltd. (the “Administrative Fee Shares”) who assisted with facilitating the acquisition and provided administrative support for its completion. The consideration shares, administrative shares and bonus shares are not subject to restrictions on resale. GMP Drug holds the rights to operate from the facility for a twelve-month term ending November 30, 2023. Core One Labs Inc. (CNSX:COOL) completed the acquisition of GMP Drug Inc. on January 13, 2023.
공시 • Dec 10Core One Labs Inc., Annual General Meeting, Feb 08, 2023Core One Labs Inc., Annual General Meeting, Feb 08, 2023.